Idarucizumab is an antibody that binds dabigatran for the reversal of anticoagulant effects of dabigatran. As a direct acting oral anticoagulant (DOAC), one of the risks associated with the use of dabigatran includes bleeding, espeically when given to patients at increased risk (elderly, chronic kidney disease, concomitant NSAID or warfarin...
- Mechanism
- Curator reviewed
Idarucizumab is a specific reversal agent for dabigatran. It is a humanized monoclonal antibody fragment (Fab) that binds to dabigatran and its acylglucuronide metabolites with higher affinity than the binding affinity of dabigatran to thrombin, neutralizing their anticoagulant effect.
- Primary indication
- For use in patients treated with Dabigatran when reversal of the anticoagulant effects of dabigatran is needed for emergency surgery/urgent procedures and in life-threatening or uncontrolled bleeding.Curator reviewed · 1 structured indication
- First approval
- Canada, 2016 · United States, 2015 · European Union, 2016
- Also known as
- aDabi-Fab
- Code names
- BI-655075
- Brand names
Resolves to
What you can answer from here — as of October 29, 2024
Which other approved drugs treat the same conditions as Idarucizumab, and which companies have late-stage candidates in those indications?
Create a free account or log in to explore the full data card.
Create Account